[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IL119961A - Pneumococcal polysaccharide - immunogenic protein conjugate - Google Patents

Pneumococcal polysaccharide - immunogenic protein conjugate

Info

Publication number
IL119961A
IL119961A IL11996192A IL11996192A IL119961A IL 119961 A IL119961 A IL 119961A IL 11996192 A IL11996192 A IL 11996192A IL 11996192 A IL11996192 A IL 11996192A IL 119961 A IL119961 A IL 119961A
Authority
IL
Israel
Prior art keywords
pro
immune responses
conjugates
pneumococcal
protein conjugate
Prior art date
Application number
IL11996192A
Other languages
English (en)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27094961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL119961(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL119961A publication Critical patent/IL119961A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL11996192A 1991-01-28 1992-01-21 Pneumococcal polysaccharide - immunogenic protein conjugate IL119961A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64657091A 1991-01-28 1991-01-28
US80794291A 1991-12-19 1991-12-19
IL10071692A IL100716A (en) 1991-01-28 1992-01-21 Vaccine of Pneumococcal Polysaccharide Conjugate

Publications (1)

Publication Number Publication Date
IL119961A true IL119961A (en) 2000-01-31

Family

ID=27094961

Family Applications (5)

Application Number Title Priority Date Filing Date
IL10071692A IL100716A (en) 1991-01-28 1992-01-21 Vaccine of Pneumococcal Polysaccharide Conjugate
IL11996192A IL119961A (en) 1991-01-28 1992-01-21 Pneumococcal polysaccharide - immunogenic protein conjugate
IL11996292A IL119962A (en) 1991-01-28 1992-01-21 Process for making a pneumococcal polysaccharide - immunogenic protein conjugate
IL11996297A IL119962A0 (en) 1991-01-28 1997-01-03 Process for making a pneumococcal polysaccharide-immunogenic protein conjugate
IL11996197A IL119961A0 (en) 1991-01-28 1997-01-03 Pneumococcal polysaccharide-immunogenic protein conjugate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL10071692A IL100716A (en) 1991-01-28 1992-01-21 Vaccine of Pneumococcal Polysaccharide Conjugate

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL11996292A IL119962A (en) 1991-01-28 1992-01-21 Process for making a pneumococcal polysaccharide - immunogenic protein conjugate
IL11996297A IL119962A0 (en) 1991-01-28 1997-01-03 Process for making a pneumococcal polysaccharide-immunogenic protein conjugate
IL11996197A IL119961A0 (en) 1991-01-28 1997-01-03 Pneumococcal polysaccharide-immunogenic protein conjugate

Country Status (23)

Country Link
US (1) US5623057A (lv)
EP (1) EP0497525B2 (lv)
JP (1) JPH0794472B2 (lv)
KR (1) KR100243958B1 (lv)
CN (1) CN1080124C (lv)
AT (1) ATE169825T1 (lv)
AU (1) AU651656B2 (lv)
CA (1) CA2059692C (lv)
CZ (1) CZ283284B6 (lv)
DE (1) DE69226668T3 (lv)
DK (1) DK0497525T4 (lv)
ES (1) ES2121820T5 (lv)
FI (1) FI107370B (lv)
HU (1) HU216101B (lv)
IE (1) IE920244A1 (lv)
IL (5) IL100716A (lv)
LV (1) LV12309B (lv)
MX (1) MX9200328A (lv)
NO (1) NO304117B1 (lv)
NZ (1) NZ241367A (lv)
SI (1) SI9210081B (lv)
SK (1) SK280659B6 (lv)
YU (1) YU49068B (lv)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US5747287A (en) * 1995-04-28 1998-05-05 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5695768A (en) * 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
WO1996040225A1 (en) * 1995-06-07 1996-12-19 Alberta Research Council Immunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
US6410025B1 (en) 1996-02-14 2002-06-25 Merck & Co., Inc. Polysaccharide precipitation process
SE9601158D0 (sv) * 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
ES2166097T5 (es) * 1996-08-27 2007-03-16 Novartis Vaccines And Diagnostics, Inc. Glicoconjugados de neisseria meningitidis de serogrupo b y procedimientos para usarlos.
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
EP0998557A2 (en) * 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
IL137809A0 (en) * 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
GB9816337D0 (en) * 1998-07-27 1998-09-23 Cortecs Uk Ltd Proteins
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
AU750762B2 (en) * 1999-03-19 2002-07-25 Smithkline Beecham Biologicals (Sa) Vaccine
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
US20040191834A1 (en) * 1999-10-28 2004-09-30 Laferriere Craig Antony Joseph Novel method
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
SK288007B6 (sk) * 2000-06-29 2012-10-02 Glaxosmithkline Biologicals S. A. Multivalent vaccine composition, process for its producing, and its use
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP1569955A2 (en) * 2002-12-03 2005-09-07 Sloan-Kettering Institute For Cancer Research Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
US7369578B2 (en) * 2003-07-01 2008-05-06 Nortel Networks Limited Digital processing of SONET pointers
PT1701968E (pt) * 2003-12-17 2015-09-11 Wyeth Llc Conjugados de transportadores de péptidos imunogénicos e métodos para produzir os mesmos
DK2336147T3 (da) 2003-12-17 2014-06-10 Wyeth Llc Beta-immunogen-peptid-bærerkonjugater og fremgangsmåder til fremstilling deraf
CA2584290A1 (en) 2004-09-22 2006-03-30 Glaxosmithkline Biologicals S.A. Staphylococcal immunogenic compositions
PT1868645E (pt) * 2005-04-08 2012-05-17 Wyeth Llc Composição conjugada de polissacárido-proteína pneumocócica polivalente
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2011253684B8 (en) * 2005-04-08 2013-07-11 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2612980C (en) 2005-06-27 2019-01-15 Glaxosmithkline Biologicals S.A. Immunogenic composition comprising a haemophilus influenzae type b saccharide conjugate
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) * 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP1962899B1 (en) 2005-12-22 2011-08-17 GlaxoSmithKline Biologicals S.A. Pneumococcal polysaccharide conjugate vaccine
CN101024079B (zh) * 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
WO2007113222A2 (en) 2006-03-30 2007-10-11 Glaxosmithkline Biologicals S.A. Immunogenic composition
AU2013200552B9 (en) * 2006-04-07 2014-07-03 Glaxosmithkline Biologicals S.A. Conjugate vaccines
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
CN101553246B (zh) * 2006-08-07 2019-05-21 哈佛大学校长及研究员协会 蛋白质基质疫苗及这种疫苗的制备和给药方法
CA2662064A1 (en) 2006-09-07 2008-03-13 Glaxosmithkline Biologicals S.A. Method of producing a combination polivirus vaccine
MX2009003730A (es) * 2006-10-10 2009-04-22 Wyeth Corp Purificacion de polisacaridos de streptococcus pneumoniae tipo 3.
CN1963500B (zh) * 2006-12-06 2010-05-12 云南沃森生物技术股份有限公司 一种肺炎链球菌荚膜多糖结合物中游离多糖含量的测定方法
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
HUE039169T2 (hu) * 2007-03-23 2018-12-28 Wyeth Llc Rövidített tisztítási eljárás Streptococcus pneumoniae tok-poliszacharidok elõállítására
WO2008129559A2 (en) 2007-04-23 2008-10-30 Serum Institute Of India Ltd Antigenic polysaccharides and process for their preparation
TW200914042A (en) 2007-05-02 2009-04-01 Glaxosmithkline Biolog Sa Vaccine
CN101784282B (zh) 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 包含肺炎链球菌荚膜多糖缀合物的疫苗
JP2012504660A (ja) 2008-10-06 2012-02-23 ユニバーシティ オブ シカゴ 細菌ｅａｐ、ｅｍｐおよび／またはａｄｓａタンパク質に関連する組成物および方法
EP2385981B1 (en) * 2008-12-18 2019-09-04 Wyeth LLC Method for controlling streptococcus pneumoniae polysaccharide molecular weight using carbon
EP2379734B1 (en) * 2008-12-18 2018-03-21 Wyeth LLC Method for controlling streptococcus pneumoniae serotype 19a polysaccharide molecular weight
EP2387417B1 (en) 2009-01-16 2016-05-11 University of Maryland, Baltimore Broad spectrum vaccine against non-typhoidal salmonella
HUE057713T2 (hu) 2009-04-03 2022-05-28 Univ Chicago A protein A (SPA) variánsaival kapcsolatos készítmények és módszerek
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
US10105412B2 (en) * 2009-06-29 2018-10-23 Genocea Biosciences, Inc. Vaccines and compositions against Streptococcus pneumoniae
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
WO2011148382A1 (en) 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.
WO2012003474A2 (en) 2010-07-02 2012-01-05 The University Of Chicago Compositions and methods related to protein a (spa) variants
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
EP2665490B1 (en) 2011-01-20 2020-03-04 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
CN103687600B (zh) 2011-03-22 2016-05-04 印度血清研究所私人有限公司 一种制备多糖的方法
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
NO3106176T3 (lv) 2011-12-06 2018-03-10
EP2804627B1 (en) 2012-01-20 2019-08-14 Genocea Biosciences Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
WO2013162746A1 (en) 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
ITMI20121597A1 (it) 2012-09-25 2014-03-26 Beta Pharma S A Coniugato tra frammento di parete cellulare batterica ed un veicolo mucopolisaccaridico e suoi usi in ambito medico
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
CA2917365A1 (en) * 2013-07-07 2015-01-15 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Synthetic vaccines against streptococcus pneumoniae type 1
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA2937190A1 (en) * 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
NZ755769A (en) * 2014-01-21 2023-06-30 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10668164B2 (en) * 2014-02-14 2020-06-02 Pfizer Inc. Immunogenic glycoprotein conjugates
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
PE20180460A1 (es) 2015-06-08 2018-03-06 Serum Inst Of India Private Ltd Metodos para mejorar la adsorcion de conjugados de polisacarido-proteina y una formulacion de vacuna multivalente obtenida con los mismos
EP3436061A4 (en) 2016-03-31 2019-12-04 Liffey Biotech Limited Saccharide-polypeptide-conjugate compositions and methods of use thereof
EP3269385A1 (en) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
EP3474890A1 (en) 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019007910A (es) 2016-12-30 2019-12-05 Sutrovax Inc Conjugados de polipeptido-antigeno con aminoacidos no naturales.
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
WO2018144799A1 (en) 2017-02-03 2018-08-09 SCHADECK, Eva, Barbara Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof
US20200061542A1 (en) * 2017-02-24 2020-02-27 Merck Sharp & Dohme Corp. Methods for improving filterability of polysaccharide-protein conjugate reactions
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN111132691A (zh) 2017-06-10 2020-05-08 创赏有限公司 提供改善的免疫原性和亲合力的具有二价或多价缀合物多糖的多价缀合物疫苗
KR20200051004A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
EP3678653A4 (en) 2017-09-07 2021-05-26 Merck Sharp & Dohme Corp. ANTIPNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN POLYSACCHARIDE-CARRIER PROTEIN IMMUNOGENIC CONJUGATES
KR20200051003A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
BR112020004502A8 (pt) 2017-09-07 2022-11-01 Merck Sharp & Dohme Polissacarídeos pneumocócicos e uso dos mesmos em conjugados imunogênicos polissacarídeo-proteína carreadora
GEP20227420B (en) 2017-12-06 2022-10-10 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN108079286B (zh) * 2018-01-19 2020-07-31 云南沃森生物技术股份有限公司 一种13价肺炎球菌多糖-蛋白结合物组合物及其制备方法和应用
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
US11642406B2 (en) 2018-12-19 2023-05-09 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2021013736A (es) 2019-05-10 2021-12-10 Glaxosmithkline Biologicals Sa Produccion de conjugados.
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
EP3900739A1 (en) 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
EP3919076A1 (en) 2020-06-02 2021-12-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
CA3191005A1 (en) 2020-08-10 2022-02-17 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
WO2022180648A1 (en) 2021-02-26 2022-09-01 Biological E Limited Activated-quenched polysaccharide and improved methods for quantification of polysaccharide in a vaccine composition
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
WO2024062494A1 (en) 2022-09-19 2024-03-28 Biological E Limited Method for the purification of capsular polysaccharides

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4324887A (en) * 1978-08-16 1982-04-13 President And Fellows Of Harvard College Type II group B Streptococci polysaccharide
US4221906A (en) * 1979-03-19 1980-09-09 American Cyanamid Company Stabilization of pneumococcal polysaccharides
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4271147A (en) * 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
PT72812B (en) * 1980-04-14 1983-02-16 Merck & Co Inc Process for preparing group b streptococcal capsular polysccha-rides
FR2495939B1 (fr) * 1980-12-11 1985-10-11 Merieux Inst Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies
NL8202527A (nl) * 1982-06-22 1984-01-16 Univ Utrecht Vaccins tegen door bacterien met kapsel-polysacchariden verwekte ziekten en werkwijze voor het bereiden daarvan.
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ES2000034A6 (es) * 1985-11-26 1987-10-01 Schweiz Serum & Impfinst Procedimiento para la preparacion de una vacuna viva contra paperas
US4755381A (en) * 1986-03-27 1988-07-05 Swiss Serum And Vaccine Institute Berne Klebsiella capsular polysaccharide vaccine
ATE107703T1 (de) * 1986-04-16 1994-07-15 Brigham & Womens Hospital Bakterielle antigene, antikörper, impfstoffe und deren herstellung.
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
ES2051909T3 (es) * 1988-04-19 1994-07-01 American Cyanamid Co Vacuna del conjugado de polisacarido-proteina de membrana externa contra la haemophilus influenzae tipo b.
US5091300A (en) * 1989-08-03 1992-02-25 Merck & Co., Inc. Radio-immuno assay for hepatitis b virus pres2 antibodies
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
JP2636128B2 (ja) * 1993-02-03 1997-07-30 株式会社アマダメトレックス パンチング金型

Also Published As

Publication number Publication date
YU8192A (sh) 1994-12-28
CZ283284B6 (cs) 1998-02-18
KR100243958B1 (ko) 2000-02-01
ES2121820T5 (es) 2010-05-28
SI9210081B (en) 2001-12-31
FI107370B (fi) 2001-07-31
EP0497525A2 (en) 1992-08-05
DK0497525T3 (da) 1998-10-26
DK0497525T4 (da) 2010-07-05
IE920244A1 (en) 1992-07-29
IL119961A0 (en) 1997-04-15
HU9200252D0 (en) 1992-04-28
KR920014829A (ko) 1992-08-25
CN1080124C (zh) 2002-03-06
SK280659B6 (sk) 2000-05-16
DE69226668D1 (de) 1998-09-24
DE69226668T2 (de) 1999-04-22
FI920353A (fi) 1992-07-29
EP0497525A3 (en) 1993-03-10
ATE169825T1 (de) 1998-09-15
US5623057A (en) 1997-04-22
CS19992A3 (en) 1992-10-14
IL100716A (en) 1999-12-22
DE69226668T3 (de) 2010-12-16
JPH0794472B2 (ja) 1995-10-11
IL119962A (en) 2000-01-31
EP0497525B2 (en) 2010-03-03
MX9200328A (es) 1992-09-01
NZ241367A (en) 1994-04-27
HU216101B (hu) 1999-04-28
NO304117B1 (no) 1998-10-26
LV12309A (lv) 1999-07-20
IL100716A0 (en) 1992-09-06
FI920353A0 (fi) 1992-01-27
NO920350L (no) 1992-07-29
ES2121820T3 (es) 1998-12-16
AU651656B2 (en) 1994-07-28
CA2059692C (en) 2004-11-16
IL119962A0 (en) 1997-04-15
HUT69968A (en) 1995-09-28
LV12309B (lv) 1999-11-20
JPH0565300A (ja) 1993-03-19
CN1064217A (zh) 1992-09-09
YU49068B (sh) 2003-08-29
CA2059692A1 (en) 1992-07-29
EP0497525B1 (en) 1998-08-19
SI9210081A (en) 1996-02-29
NO920350D0 (no) 1992-01-27
AU1046792A (en) 1992-07-30

Similar Documents

Publication Publication Date Title
HUT69968A (en) Pneumococcal polysaccharide conjugate vaccine
LU90808I2 (fr) Conjugue serotype 18c d'oligosaccharide pneumococcique
KR920003982A (ko) 면역원성 콘쥬게이트 및 이를 함유하는 백신 조성물
PL304419A1 (en) Urease based vaccine against heliobacter infections
FI914564A0 (fi) Foerbaettrade konjugerade oligosackaridvacciner.
PL316906A1 (en) Immunogenous compositions of group a streptococci polysaccharides and method of obtaining them
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
DE69333402D1 (en) Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired